EORTC-NCI-AACR 2010: Tivozanib Biomarker Identifies Tumor-infiltrating Myeloid Cells Contributing to Tivozanib Resistance in Both Preclinical Models and Human Renal Cell Carcinoma
Category: Presentation
IKCS 2010: Effect of Hypertension, Nephrectomy, and Prior Treatment on the Efficacy of Tivozanib (AV-951) in a Phase 2 Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
IKCS 2010: Effect of Hypertension, Nephrectomy, and Prior Treatment on the Efficacy of Tivozanib (AV-951) in a Phase 2 Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma
IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma
ASCO 2010: Activity of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma (RCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial (RDT)
ASCO 2010: Activity of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma (RCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial (RDT)
ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors
ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors
ASCO GU 2010: Effect of hypertension, nephrectomy and prior treatment on the efficacy of tivozanib (AV-951) in a phase 2 randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC)
ASCO GU 2010: Effect of hypertension, nephrectomy and prior treatment on the efficacy of tivozanib (AV-951) in a phase 2 randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC)